Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
87.02 USD | -0.30% |
|
-12.73% | -12.45% |
06:09am | TD Cowen Downgrades Merck & Co. to Hold From Buy, Adjusts Price Target to $100 From $121 | MT |
Feb. 07 | Health Rounds: Vaccine keeps advanced kidney cancer from recurring | RE |
1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
---|---|---|---|---|---|---|---|---|
24 | ||||||||
26 | ||||||||
24 | ||||||||
21 | ||||||||
27 | ||||||||
19 | ||||||||
19 | ||||||||
20 | ||||||||
26 | ||||||||
22 | ||||||||
22 | ||||||||
25 | ||||||||
21 | ||||||||
15 | ||||||||
19 | ||||||||
18 | ||||||||
17 | ||||||||
17 | ||||||||
16 | ||||||||
Average | 21 | |||||||
Weighted average by Cap. | 23 |
- Stock Market
- Equities
- MRK Stock
- Sector Merck & Co., Inc.
- Sector revisions